These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28341983)

  • 1. [Management of different cardiovascular risk factors with a combination tablet (polypill)].
    Bramlage P; März W; Westermann D; Weisser B; Wirtz JH; Zeymer U; Baumgart P; van Mark G; Laufs U; Krämer BK; Unger T
    Herz; 2018 May; 43(3):246-257. PubMed ID: 28341983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of a Polypill to Reduce Cardiovascular Events: A Review of Clinical Trials.
    Kelly MS; Dacey A; Siana A; Ojeda J
    J Cardiovasc Pharmacol; 2024 Jan; 83(1):8-15. PubMed ID: 37924288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis.
    Salim H; Musmar B; Saifi M; Ayyad M; Ruzieh M; Azar J; Nazzal Z
    Curr Cardiol Rev; 2024; 20(2):61-71. PubMed ID: 38265377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypill Strategy in Secondary Cardiovascular Prevention.
    De la Rosa A; Arrington K; Desai R; Acharya PC
    Curr Cardiol Rep; 2024 May; 26(5):443-450. PubMed ID: 38557814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation.
    Sarfo FS; Nichols M; Opare-Addo PA; Ovbiagele B
    Stroke; 2023 Feb; 54(2):407-414. PubMed ID: 36689592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of polypills for the prevention of atherosclerotic cardiovascular disease.
    Agnello F; Finocchiaro S; Laudani C; Legnazzi M; Mauro MS; Rochira C; Scalia L; Capodanno D
    Am Heart J; 2023 Dec; 266():74-85. PubMed ID: 37634656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension therapy using fixed-dose polypills that contain at least three medications.
    O'Hagan ET; McIntyre D; Nguyen T; Chow CK
    Heart; 2023 Aug; 109(17):1273-1280. PubMed ID: 36810213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.
    ; Rodgers A; Patel A; Berwanger O; Bots M; Grimm R; Grobbee DE; Jackson R; Neal B; Neaton J; Poulter N; Rafter N; Raju PK; Reddy S; Thom S; Vander Hoorn S; Webster R
    PLoS One; 2011; 6(5):e19857. PubMed ID: 21647425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redefining the polypill: pros and cons in cardiovascular precision medicine.
    Birla S; Angural A; Madathumchalil A; Shende RV; Shastry SV; Mahadevappa M; Shambhu SK; Vishwanath P; Prashant A
    Front Pharmacol; 2023; 14():1268119. PubMed ID: 37799963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polypill and Combination Therapy: Blood Pressure and Cardiovascular Risk Reduction.
    Park J; Yang CW; Huan Y; Aggarwal S
    Curr Cardiol Rep; 2023 Dec; 25(12):1851-1858. PubMed ID: 37991626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management.
    Narita K; Hoshide S; Kario K
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific development of the CNIC cardiovascular polypill: from conceptualization to clinical efficacy.
    Castellano JM; Fuster V
    Rev Esp Cardiol (Engl Ed); 2023 Dec; 76(12):1055-1060. PubMed ID: 37866619
    [No Abstract]   [Full Text] [Related]  

  • 13. Polypill is not just for cardiovascular disease.
    Cafferty FH; Langley RE
    BMJ; 2017 Jun; 357():j2733. PubMed ID: 28592412
    [No Abstract]   [Full Text] [Related]  

  • 14. Information regarding polypill treatment is lacking.
    Dufour I; Devresse A
    Kidney Int; 2023 Jun; 103(6):1201. PubMed ID: 37210198
    [No Abstract]   [Full Text] [Related]  

  • 15. Modular Titratable Polypills for Personalized Medicine and Simplification of Complex Medication Regimens.
    Karavasili C; Babaee S; Kutty S; Chu JN; Min S; Fitzgerald N; Morimoto J; Inverardi N; Traverso G
    Adv Healthc Mater; 2023 Oct; 12(27):e2301101. PubMed ID: 37526266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Polypill: A New Alternative in the Prevention and Treatment of Cardiovascular Disease.
    Espinosa EVP; Matute EM; Sosa Guzmán DM; Khasawneh FT
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ANMCO Scientific statement on combination therapies and polypill in secondary prevention].
    De Luca L; Di Fusco SA; Iannopollo G; Mistrulli R; Rizzello V; Aimo A; Navazio A; Bilato C; Corda M; Di Marco M; Geraci G; Iacovoni A; Milli M; Pascale V; Riccio C; Scicchitano P; Tizzani E; Gabrielli D; Grimaldi M; Colivicchi F; Oliva F
    G Ital Cardiol (Rome); 2024 May; 25(5):367-381. PubMed ID: 38639128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter].
    Zhu LL; Zhou Q
    Vasc Health Risk Manag; 2023; 19():659-660. PubMed ID: 37790123
    [No Abstract]   [Full Text] [Related]  

  • 19. The Benefits of Polypill: Adherence and Chronotherapy [Response to Letter].
    Lopez-Jaramillo P; Lopez-Lopez JP
    Vasc Health Risk Manag; 2023; 19():661-662. PubMed ID: 37854581
    [No Abstract]   [Full Text] [Related]  

  • 20. Polypill for Cardiovascular Disease Prevention in an Underserved Population.
    Bilal U; Cainzos-Achirica M
    N Engl J Med; 2020 Jan; 382(1):94-95. PubMed ID: 31875510
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.